COVID-19相关高炎症中靶向粒细胞巨噬细胞集落刺激因子的治疗:挑战与机遇
本文探讨了在COVID-19相关高炎症中靶向粒细胞巨噬细胞集落刺激因子(GM-CSF)的科学依据。作者认为及时免疫调节可预防重度COVID-19患者进展为ARDS,但GM-CSF在稳态和宿主防御中也有作用,抑制它可能存在风险,并强调需要患者风险分层算法。
要点
- 重度COVID-19亚组患者的过度宿主炎症反应可能促发ARDS和多器官衰竭。
- GM-CSF轴连接T细胞驱动的急性肺部炎症与单核巨噬细胞激活的正反馈循环。
- 抑制GM-CSF可能影响稳态和宿主防御,需风险分层指导临床 trials。
核心结论
- 靶向GM-CSF治疗COVID-19相关高炎症具有科学依据,但需权衡抑制GM-CSF对宿主防御的潜在风险。
- 在COVID-19中开展GM-CSF抑制的临床试验面临挑战,尤其需要患者风险分层算法。
研究设计与样本
- 本文为综述,讨论靶向GM-CSF治疗COVID-19相关高炎症的科学依据、潜在风险及临床试验挑战。
主要发现
- 重度COVID-19亚组患者的过度宿主炎症反应可能促发ARDS和多器官衰竭。
- 及时对高炎症患者进行免疫调节治疗可能预防疾病进展至ARDS并避免有创通气。
- GM-CSF可连接T细胞驱动的急性肺部炎症与自分泌、自我放大的细胞因子环路,导致单核细胞和巨噬细胞激活。
- GM-CSF轴已在细胞因子风暴综合征和慢性炎症性疾病中被靶向。
- GM-CSF在稳态和宿主防御中也有关键作用,抑制它可能带来风险。
临床怎么用
- 对重度COVID-19高炎症患者,可考虑及时免疫调节以预防ARDS和有创通气需求。
- 靶向GM-CSF治疗需基于患者风险分层算法,权衡获益与宿主防御受损风险。
局限性
- 本文为综述,未报告原始研究数据。
- 在COVID-19中抑制GM-CSF的潜在风险(如影响宿主防御)尚需临床 trials 评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic is a global public health crisis, with considerable mortality and morbidity exerting pressure on health-care resources, including critical care. An excessive host inflammatory response in a subgroup of patients with severe COVID-19 might contribute to the development of acute respiratory distress syndrome (ARDS) and multiorgan failure. Timely therapeutic intervention with immunomodulation in patients with hyperinflammation could prevent disease progression to ARDS and obviate the need for invasive ventilation. Granulocyte macrophage colony-stimulating factor (GM-CSF) is an immunoregulatory cytokine with a pivotal role in initiation and perpetuation of inflammatory diseases. GM-CSF could link T-cell-driven acute pulmonary inflammation with an autocrine, self-amplifying cytokine loop leading to monocyte and macrophage activation. This axis has been targeted in cytokine storm syndromes and chronic inflammatory disorders. Here, we consider the scientific rationale for therapeutic targeting of GM-CSF in COVID-19-associated hyperinflammation. Since GM-CSF also has a key role in homoeostasis and host defence, we discuss potential risks associated with inhibition of GM-CSF in the context of viral infection and the challenges of doing clinical trials in this setting, highlighting in particular the need for a patient risk-stratification algorithm.
引用
- Mehta P, Porter JC, Manson JJ, et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med. 2020. PMID: 32559419. doi:10.1016/S2213-2600(20)30267-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。